Form 6-K GLAXOSMITHKLINE PLC For: Oct 18
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending 18 October 2016
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of
principal executive offices)
Indicate by check
mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate by check
mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline
plc (the 'Company')
Transaction notification
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Sir Andrew Witty
|
|
b)
|
Position/status
|
Chief Executive Officer
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 October 2016
on Ordinary Shares held in the Company's 2009 Performance Share
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.00
|
3.852
|
||
£17.00
|
210.425
|
||
£17.00
|
562.209
|
||
£17.00
|
1288.273
|
||
£17.00
|
3864.847
|
||
£17.00
|
5283.681
|
||
£17.00
|
5722.843
|
||
d)
|
Aggregated information
Aggregated volume Price
|
16,936.13
£17.00
|
|
e)
|
Date of the transaction
|
2016-10-13
|
|
f)
|
Place of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Ms E Walmsley
|
|
b)
|
Position/status
|
CEO Designate
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 October 2016
on Ordinary Shares held in the Company's 2009 Performance Share
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.00
|
711.971
|
||
£17.00
|
1339.653
|
||
£17.00
|
1373.598
|
||
£17.00
|
2344.931
|
||
d)
|
Aggregated information
Aggregated volume Price
|
5,770.153
£17.00
|
|
e)
|
Date of the transaction
|
2016-10-13
|
|
f)
|
Place of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr S Dingemans
|
|
b)
|
Position/status
|
Chief Financial Officer
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 October 2016
on Ordinary Shares held in the Company's 2009 Performance Share
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.00
|
2267.631
|
||
£17.00
|
2325.081
|
||
£17.00
|
2518.157
|
||
d)
|
Aggregated information
Aggregated volume Price
|
7,110.869
£17.00
|
|
e)
|
Date of the transaction
|
2016-10-13
|
|
f)
|
Place of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr R G Connor
|
|
b)
|
Position/status
|
President, Global Manufacturing & Supply
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 October 2016
on Ordinary Shares held in the Company's 2009 Performance Share
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.00
|
1042.651
|
||
£17.00
|
1069.072
|
||
£17.00
|
1369.301
|
||
d)
|
Aggregated information
Aggregated volume Price
|
3,481.024
£17.00
|
|
e)
|
Date of the transaction
|
2016-10-13
|
|
f)
|
Place of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr L Debruyne
|
|
b)
|
Position/status
|
President, Global Vaccines GSK
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 October 2016
on Ordinary Shares held in the Company's 2009 Performance Share
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.00
|
273.464
|
||
£17.00
|
298.195
|
||
£17.00
|
344.671
|
||
d)
|
Aggregated information
Aggregated volume Price
|
916.330
£17.00
|
|
e)
|
Date of the transaction
|
2016-10-13
|
|
f)
|
Place of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr N Hirons
|
|
b)
|
Position/status
|
SVP, Global Ethics & Compliance
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 October 2016
on Ordinary Shares held in the Company's 2009 Performance Share
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.00
|
518.340
|
||
£17.00
|
564.838
|
||
d)
|
Aggregated information
Aggregated volume Price
|
1,083.178
£17.00
|
|
e)
|
Date of the transaction
|
2016-10-13
|
|
f)
|
Place of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr S A Hussain
|
|
b)
|
Position/status
|
President, Global Pharmaceuticals
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 October 2016
on Ordinary Shares held in the Company's 2009 Performance Share
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.00
|
2105.069
|
||
£17.00
|
2429.724
|
||
£17.00
|
2738.614
|
||
d)
|
Aggregated information
Aggregated volume Price
|
7,273.407
£17.00
|
|
e)
|
Date of the transaction
|
2016-10-13
|
|
f)
|
Place of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr D S Redfern
|
|
b)
|
Position/status
|
Chief Strategy Officer
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 October 2016
on Ordinary Shares held in the Company's 2009 Performance Share
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.00
|
748.492
|
||
£17.00
|
850.396
|
||
£17.00
|
992.738
|
||
d)
|
Aggregated information
Aggregated volume Price
|
2,591.626
£17.00
|
|
e)
|
Date of the transaction
|
2016-10-13
|
|
f)
|
Place of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Ms C Thomas
|
|
b)
|
Position/status
|
SVP, HR
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 October 2016
on Ordinary Shares held in the Company's 2009 Performance Share
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.00
|
1067.932
|
||
£17.00
|
1133.866
|
||
£17.00
|
1249.482
|
||
d)
|
Aggregated information
Aggregated volume Price
|
3,451.28
£17.00
|
|
e)
|
Date of the transaction
|
2016-10-13
|
|
f)
|
Place of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr P C Thomson
|
|
b)
|
Position/status
|
SVP, Communications & Government Affairs
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 October 2016
on Ordinary Shares held in the Company's 2009 Performance Share
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.00
|
509.321
|
||
£17.00
|
656.026
|
||
£17.00
|
718.885
|
||
d)
|
Aggregated information
Aggregated volume Price
|
1,884.232
£17.00
|
|
e)
|
Date of the transaction
|
2016-10-13
|
|
f)
|
Place of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Dr P J T Vallance
|
|
b)
|
Position/status
|
President, Pharmaceuticals R&D
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 October 2016
on Ordinary Shares held in the Company's 2009 Performance Share
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.00
|
2300.167
|
||
£17.00
|
2358.444
|
||
£17.00
|
2909.770
|
||
d)
|
Aggregated information
Aggregated volume Price
|
7,568.381
£17.00
|
|
e)
|
Date of the transaction
|
2016-10-13
|
|
f)
|
Place of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mrs V A Whyte
|
|
b)
|
Position/status
|
Company Secretary
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 October 2016
on Ordinary Shares held in the Company's 2009 Performance Share
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.00
|
137.240
|
||
£17.00
|
145.217
|
||
£17.00
|
153.140
|
||
d)
|
Aggregated information
Aggregated volume Price
|
435.597
£17.00
|
|
e)
|
Date of the transaction
|
2016-10-13
|
|
f)
|
Place of the transaction
|
n/a
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: October
18, 2016
By: VICTORIA
WHYTE
----------------------
Victoria Whyte
Authorised
Signatory for and on
behalf
of GlaxoSmithKline plc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Earth Day 2024: How KFC is Championing Sustainability
- Ripple CTO Addresses XRP and Ripple Naming Confusion
- Accelerator Grand Prix ACF AutoTech Announces Winners for 7th Annual Contest that Highlights Top Global Automotive Startup Companies
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!